

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2022/2023 influenza season**

as of August 21, 2023

|                                   | A(H1N1)pdm09 |             |           |           |             |              | A(H3N2)     |             |           |           |             |               | B         |             |           |           |             |
|-----------------------------------|--------------|-------------|-----------|-----------|-------------|--------------|-------------|-------------|-----------|-----------|-------------|---------------|-----------|-------------|-----------|-----------|-------------|
|                                   | Baloxavir    | Oseltamivir | Peramivir | Zanamivir | Laninamivir | Amantadine   | Baloxavir   | Oseltamivir | Peramivir | Zanamivir | Laninamivir | Amantadine    | Baloxavir | Oseltamivir | Peramivir | Zanamivir | Laninamivir |
| <b>Resistant (%)</b>              | 0            | 0           | 0         | 0         | 0           | 36<br>(100%) | 7<br>(1.5%) | 0           | 0         | 0         | 0           | 275<br>(100%) | 0         | 0           | 0         | 0         | 0           |
| <b>Number of viruses tested</b>   | 38           | 53          | 53        | 35        | 35          | 36           | 476         | 274         | 274       | 274       | 274         | 275           | 41        | 39          | 39        | 39        | 39          |
| <b>Number of viruses reported</b> | 111          |             |           |           |             |              | 3,181       |             |           |           |             |               | 84        |             |           |           |             |

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.